Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$61.99−1.66 (-2.61%)
Close on Nov 18, 2026Market cap $1.77BP/E 158.9Yield –
Eton Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Eton Pharmaceuticals's total assets was $115.81M at Jun 30, 2026. For fiscal 2025 it was $92.11M, up 21.0% from the year before. The highest annual figure on record is $92.11M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.11M | +21.0% |
| FY2024 | Dec 31, 2024 | $76.12M | +139.8% |
| FY2023 | Dec 31, 2023 | $31.74M | +26.8% |
| FY2022 | Dec 31, 2022 | $25.03M | -8.9% |
| FY2021 | Dec 31, 2021 | $27.47M | +4.4% |
| FY2020 | Dec 31, 2020 | $26.32M | +54.2% |
| FY2019 | Dec 31, 2019 | $17.07M | -39.7% |
| FY2018 | Dec 31, 2018 | $28.33M | +110.7% |
| FY2017 | Dec 31, 2017 | $13.44M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $115.81M | +13.9% |
| Q1 FY2026 | Mar 31, 2026 | $97.71M | +16.3% |
| Q4 FY2025 | Dec 31, 2025 | $92.11M | +21.0% |
| Q3 FY2025 | Sep 30, 2025 | $104.51M | +191.6% |
| Q2 FY2025 | Jun 30, 2025 | $101.68M | +219.5% |
| Q1 FY2025 | Mar 31, 2025 | $84.03M | +172.9% |
| Q4 FY2024 | Dec 31, 2024 | $76.12M | +139.8% |
| Q3 FY2024 | Sep 30, 2024 | $35.84M | +13.7% |
| Q2 FY2024 | Jun 30, 2024 | $31.82M | +2.9% |
| Q1 FY2024 | Mar 31, 2024 | $30.79M | +28.7% |
| Q4 FY2023 | Dec 31, 2023 | $31.74M | +26.8% |
| Q3 FY2023 | Sep 30, 2023 | $31.53M | +46.5% |
| Q2 FY2023 | Jun 30, 2023 | $30.93M | +34.2% |
| Q1 FY2023 | Mar 31, 2023 | $23.93M | +3.2% |
| Q4 FY2022 | Dec 31, 2022 | $25.03M | -8.9% |
| Q3 FY2022 | Sep 30, 2022 | $21.52M | -19.1% |
| Q2 FY2022 | Jun 30, 2022 | $23.05M | -22.9% |
| Q1 FY2022 | Mar 31, 2022 | $23.20M | -25.6% |
| Q4 FY2021 | Dec 31, 2021 | $27.47M | +4.4% |
| Q3 FY2021 | Sep 30, 2021 | $26.61M | +133.5% |
| Q2 FY2021 | Jun 30, 2021 | $29.91M | +105.4% |
| Q1 FY2021 | Mar 31, 2021 | $31.19M | +80.9% |
| Q4 FY2020 | Dec 31, 2020 | $26.32M | +54.2% |
| Q3 FY2020 | Sep 30, 2020 | $11.40M | -15.6% |
| Q2 FY2020 | Jun 30, 2020 | $14.56M | -20.2% |
| Q1 FY2020 | Mar 31, 2020 | $17.24M | -25.1% |
| Q4 FY2019 | Dec 31, 2019 | $17.07M | -39.7% |
| Q3 FY2019 | Sep 30, 2019 | $13.51M | +79.5% |
| Q2 FY2019 | Jun 30, 2019 | $18.24M | +35.7% |
| Q1 FY2019 | Mar 31, 2019 | $23.02M | – |
| Q4 FY2018 | Dec 31, 2018 | $28.33M | – |
| Q3 FY2018 | Sep 30, 2018 | $7.53M | – |
| Q4 FY2017 | Dec 31, 2017 | $13.44M | – |
See a number that looks wrong?